Prothena Corp Public (PRTA) Profit After Tax (2012 - 2026)
Prothena Corp Public (PRTA) posted quarterly Profit After Tax of $32.7 million for Q1 2026, up 154.36% year-over-year from $12.9 million in Q1 2025, and up 251.56% quarter-over-quarter from -$21.6 million in Q4 2025.
Analysis
Prothena Corp Public (PRTA) Profit After Tax (2012 - 2026) Analysis & Trends
Prothena Corp Public's Profit After Tax history runs 15 years deep, the most recent figure standing at $32.7 million for Q1 2026.
- In Q1 2026, Profit After Tax rose 154.36% year-over-year to $32.7 million; the TTM figure through Mar 2026 stood at -$151.2 million (down 37.1% YoY), while the FY2025 annual figure was -$244.1 million, down 99.57% from the prior year.
- Profit After Tax for Q1 2026 stood at $32.7 million, up from -$21.6 million in the prior quarter.
- The five-year high for Profit After Tax was $66.9 million in Q2 2024, with the low at -$125.8 million in Q2 2025.
- The 5-year median for Profit After Tax is -$45.8 million (2022), against an average of -$35.2 million.
- The sharpest annual moves came in 2023 and 2024: Profit After Tax sank 1162.78% in 2023, then surged 222.51% in 2024.
- Prothena Corp Public's Profit After Tax stood at $6.3 million in 2022, then tumbled by 1162.78% to -$67.5 million in 2023, then climbed by 14.11% to -$58.0 million in 2024, then surged by 62.75% to -$21.6 million in 2025, then surged by 251.56% to $32.7 million in 2026.
- Business Quant data shows PRTA's Profit After Tax at $32.7 million in Q1 2026, -$21.6 million in Q4 2025, and -$36.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Prothena Corp Public | 505.55 Mn | 217.35 Mn | - | -18.58 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -18.58 Mn |
| Mar 31, 2026 | 32.72 Mn |
| Dec 31, 2025 | -21.59 Mn |
| Sep 30, 2025 | -36.54 Mn |
| Jun 30, 2025 | -125.77 Mn |
| Mar 31, 2025 | -60.20 Mn |
| Dec 31, 2024 | -57.96 Mn |
| Sep 30, 2024 | -59.00 Mn |
| Jun 30, 2024 | 66.89 Mn |
| Mar 31, 2024 | -72.24 Mn |
| Dec 31, 2023 | -67.48 Mn |
| Sep 30, 2023 | 21.91 Mn |
| Jun 30, 2023 | -54.60 Mn |
| Mar 31, 2023 | -46.86 Mn |
| Dec 31, 2022 | 6.35 Mn |
| Sep 30, 2022 | -45.76 Mn |
| Jun 30, 2022 | -41.24 Mn |
| Mar 31, 2022 | -36.29 Mn |
| Dec 31, 2021 | -33.18 Mn |
| Sep 30, 2021 | 109.25 Mn |